STAT+: GSK sees its return to cancer start to pay off

It could soon pick up approval for its sixth cancer drug.

How this summary was made: extractive summary — built from the sources' own reporting. It is drawn only from the reporting of the sources listed below — read the originals for full detail. How we summarize →

Every article behind this summary — 1 article from 1 outlet